Researchers from Australian National University and Canberra Health Services are launching a clinical trial for PMR-116, a drug targeting the MYC protein linked to 70% of cancers. Using a "basket" trial design, the study focuses on treatment-resistant cancers. The drug disrupts tumour growth by blocking ribosomal biogenesis, showing promise in early results.